Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Roundhill NVDA WeeklyPay ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Roundhill NVDA WeeklyPay ETF trades at $34.89 (market cap $116.11M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 8.4× Roundhill NVDA WeeklyPay ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Roundhill NVDA WeeklyPay ETF for 52 Days on average.
| MRVI | NVDW | |
|---|---|---|
Market Cap | $972.90M | $116.11M |
Volume | 4,325,710 | 41,612 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $52.33 |
52-Week Low | $2.83 | $31.88 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NVDW trades at $36.64 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong sell signals from moving averages, though RSI suggests potential oversold conditions. The ETF generates weekly dividend income from Nvidia exposure but carries leverage risks. Recent news highlights its high-yield potential amid Nvidia's strong earnings performance.
The outlook remains cautious due to leveraged structure and dependency on Nvidia volatility. While weekly dividends offer income appeal, NAV erosion during Nvidia downturns presents significant risk. Investors should weigh high yield potential against elevated volatility exposure in this specialized income vehicle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
